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Introduction
Acute arterial hypertension (AH) occurs in many clinical settings, 
some of  which include the operating room, intensive care and 
emergency care units. The episodes of  acute AH may occur in pa-
tients with pre-existing hypertension or as a de novo phenomena 
[1,2]. Early recognition and timely intervention in these patients 
are very important to prevent devastating complications. 
In United States, the incidence of  chronic AH among the adult 
population (>20 years age) reaches approximately 29% and the 
numbers are still growing. 72 million people in the country and 1 
billion people worldwide are affected by chronic AH [3]. Among 
these 29% of  people suffering from AH, only 58% undergo treat-
ment, and target blood pressure (BP) values  (<140/90 mm Hg) 
are achieved in only 33% of  Caucasians, 28% in African Ameri-
cans, and 18% of  Mexican Americans [4]. Up to 55,000 deaths 
each year are directly caused by AH, while it is considered a major 
contributing factor in at least another 300,000 deaths annually in 
United States [5].
High blood pressure affects most of  the organ systems in hu-
man body and, constitutes the most important reason for office 
visits and prescription of  medications.  Chronically hypertensive 
patients are more prone to acute hypertensive episodes (AHE). 
The incidence of  AHE (alternatively, named hypertensive crisis) 
in these patients approaches 1% [6,7]. Noteworthy that the AHE 
may occur in patients without any past history of  AH. The Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of  High Blood Pressure  (JNC-7) classified blood pres-
sure into four categories: normotensive, pre-hypertensive, and hy-
pertensive stage I and stage II (Table 1). The hypertensive crisis is 
further divided into two types depending on the blood pressure 
and end organ damage – hypertensive emergency and hyperten-
sive urgency. A hypertensive urgency is defined as an increase in 
systolic BP (SBP) above 180 mmHg or diastolic BP (DBP) above 
>110 mm Hg with no evidence of  end organ damage to brain, 
heart, kidney, or eyes [3]. Hypertensive emergency is defined as an 
elevation of  SBP >180 mmHg or DBP >120 mmHg associated 
with an end organ damage. 
Hypertensive crises most frequently confronted by the emergency 
departments account for 27.5% of  all nonsurgical emergencies 
and 3% of  all emergency room visits. One of  the most com-
mon reasons for postponing elective surgery is uncontrolled hy-
pertension [8]. There are multiple anesthesia concerns related to 
hypertension in the perioperative period. Sympathetic overactiva-
tion occurring during anesthesia induction can increase the SBP 
in normotensive patients by up to 20-30mm Hg. In contrast, in 
hypertensive patients the SBP values could increase by up to 90 
mmHg [9]. Because of  anesthesia-induced sympathetic suppres-
sion and blunting of  the baroreceptor reflex, these patients may 
experience episodes of  sustained arterial hypotension following 
anesthesia induction and during anesthesia maintenance. In the 
postoperative period, the patients suffering from AH may present 
with rebound hypertension because of  fading of  the anesthetic 
drug effects, pain, excitement, hypercapnia and sympathetic acti-
vation triggered by hypothermia and shivering. The blood pres-
sure fluctuations occur more frequently in patients with a history 
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of  preexisting AH, which makes them prone to postoperative 
complications [10,11]. 
Autoregulatory processes are abundant within many biologi-
cal systems. They comprise inherent adaptive mechanisms that 
work to adjust that organ system response to stimuli to maintain 
the principal biological variables within the normal range. The 
efficacy of  autoregulatory mechanisms depend on the extent of  
stimuli and varies among organ systems. The important organs 
responsible for the overall homeostasis, namely, the brain, heart 
and kidney require specific minimal amounts of  perfusion and 
oxygen to maintain their optimal function. The cerebral autoregu-
lation curve shifts to the right in patients with chronic hyperten-
sion [12,13]. Special care should be taken in selecting the optimal 
antihypertensive therapy for acute hypertensive episodes. Under 
normal conditions, the cerebral autoregulation is well maintained 
within the mean BP range of  60-160 mmHg. In cases of  AHE, 
there is an acute failure of  autoregulatory mechanisms which 
causes acute cerebral hyperemia, cerebral edema, blood-brain bar-
rier dysfunction and irreversible damage of  the nervous tissue 
[13,6].  
Pathophysiology of  Acute Hypertension
Even though AH is the most prevalent disease in the United 
States, the etiopathology of  this disease is poorly understood till 
now and considered multifactorial [6,14,15,16]. AHE is precipi-
tated by a sudden increase in systemic vascular resistance (SVR) 
resulting from mechanical stress and injury, endothelial damage, 
renin-angiotensin activation, oxidative stress and this causes fail-
ure in cerebral blood flow autoregulation [14,15]. Although, AHE 
is more characteristic for patients with a history of  hypertension, 
it may still occur in normotensive patients. Vascular endothelial 
injury results from repeated episodes of  acute hypertension which 
is associated with elevated SVR. As BP increases, vessel walls are 
subjected to increased stress, which leads to the release of  vaso-
constrictors resulting in further endothelial damage [6,14,17]. If  
not promptly treated, AHE activates the systemic hemocoagula-
tion and other mechanisms including increased arteriolar perme-
ability, upregulation of  multiple inflammatory mechanisms, in-
duction of  oxidative stress, and overproduction of  inflammatory 
cytokines [6]. Platelet aggregation and fibrinogen polymerization 
cause further vasoconstriction, and thrombosis aggravating vas-
cular injury and decreasing blood flow to critical organs [6,14]. If  
this vicious cycle is not terminated, autoregulatory dysfunction 
becomes imminent [18].
Evaluation of  Patients With AHE
Early detection and treatment of  AHE is very important to pre-
vent further damage to end organs. Proper history and physical 
examination gives very good idea about the current situation. A 
focused history should be obtained regarding AH, cardiovascular 
disorders, endocrine pathology (diabetes, adrenal tumors, pheo-
chromocytoma), previous surgery, use of  recreational drugs (co-
caine, amphetamines, and phencyclidine), current medications 
(MAO inhibitors) and patient’s compliance to the medications, 
particularly antihypertensives.
In emergency situations, patients may present to the emergen-
cy department with nausea and vomiting, headache, chest pain, 
dyspnea, vertigo, and neurologic symptoms [19]. Hypertensive 
emergency cases are differentiated from the hypertensive urgency 
patients by thorough physical examination to identify the pres-
ence of  end organ damage by referring cardiovascular, pulmo-
nary, neurologic and fundoscopic examination [20].  The organs 
most susceptible to end-organ damage associated with hyperten-
sive emergencies include the eye, kidney, heart, and brain [13,18]. 
Patients with a history of  hypertension may tolerate SBP >200 
mmHg or DBP of  >150 mmHg without developing clinical signs 
and symptoms. There are no standard guidelines for laboratory 
investigations in these patients. Complete blood count, electro-
lytes, creatinine, and urine analysis along with EKG, and chest 
x-ray are used to evaluate the end organ damage. Further investi-
gations can be ordered depending on the systems at risk during an 
AHE including echocardiogram, abdominal ultrasound, brain and 
thoraco-abdominal CT scan or MRI. 
Hypertensive emergencies associated with end organ damage are 
presented in Table.2
Management of  AHE
According to JNC-7, the treatment of  hypertensive emergencies 
include immediate intervention with a goal of  reducing SBP by 
10-15%, but no more than 25% within the first hour. Reduction 
of  the absolute BP to 160/110 mmHg should be done gradually 
over the following two to six hours [6,14,15,18,21,22,23,24,25]. 
In cases of  aortic dissection, the SBP should be reduced to less 
than 120 mmHg within twenty minutes. In hypertensive emergen-
cies associated with ischemic stroke, BP must be decreased to less 
than 180/110 before thrombolytic therapy may be administered 
[15,18,22,24,25]. If  BP reduction occurs too quickly, there may be 
a significant decrease in blood flow to tissues resulting in tissue 
damage and cell death [14,15,18,22]. Since overshooting a target 
BP (hypoperfusion) is associated with poor results, many treat-
ment protocols require invasive arterial blood pressure monitor-
ing [25,26].
Hypertensive emergencies should be treated aggressively, using 
quick-onset intravenous medications, whereas hypertensive ur-
gencies do not always require such aggressive treatment. Longer 
acting oral medications such as labetalol and clonidine may be 
Table 1: Classification of  Blood Pressure for Adults (Age ≥18 years)
Category Systolic blood Pressure (mmHg) Diastolic Blood Pressure(mmHg)
Normal <120 <80
Pre-hypertension 120-139 80-89
Hypertension- stage I 140-159 90-99
Hypertension- Stage II ≥160 ≥100
Hypertensive Urgency >180 ≥110
Hypertensive emergency >180 with end organ damage ≥120 with end organ damage
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more appropriate in situations of  hypertensive urgency. However, 
caution should be exercised when using anti-hypertensive agents 
in the acute setting. An overly aggressive treatment approach may 
lead to organ hypoperfusion [27]. Once the immediate threat of  
organ damage is diminished, BP should be gradually controlled to 
the baseline within a period of  24–48 hours [28]. Characteristics 
of  an ideal intravenous hypertensive agent are shown in Table 
3 [29,30]. Currently there are multiple intravenous medications 
for treatment of  acute hypertension in the emergency setting, 
and their main characteristics, advantages and disadvantages are 
shown in the Table 4.
Choosing the optimal drug for therapy among multiple intrave-
nous anti-hypertensive agents to treat the AHE depends on the 
patient’s medical conditions as well as the preference of  individual 
prescribers and institutional guidelines [13,25]. Calcium-channel 
blockers inhibit the L-type calcium channels, and the subclass 
of  dihydropyridines (Clevidipine, Nicardipine, Nifedipine etc.) 
Table 2: Systemic effects of  hypertensive emergencies
System Effects 
Cardio-vascular system Acute myocardial infarction (MI)
Aortic dissection
Left ventricular failure with pulmonary edema
Preeclampsia and Eclampsia.
Central nervous system Ischemic and hemorrhagic stroke
Cerebral edema and neurological dysfunction (hyper-
tensive encephalopathy), papilledema
Seizures. 
Renal Acute renal failure
Table 3: Systemic effects of  hypertensive emergencies
1. Rapid onset and offset of  action
2. Low risk of  hypotension
3. Minimal drug interactions
4. Safe with low or no adverse reactions
5. Easily titrated and adjustable
6. Minimal drug interactions
7. Preserves renal and hepatic function
8. High arteriolar selectivity 
9. Adequate cost-benefit ratio
10. Easy transition to oral therapy
11. Predictable dose response
12. No or minimal effects on intracranial pressure
Table 4: Intravenous antihypertensive medications.
Drug Mechanism of  action/
Class
Use Contraindications Dose Onset / 
Duration
Adverse Effects
C l e v i d i -
pine bu-
tyrate
Selective L-type Ca2+ 
channel antagonist. 3rd 
generation DHP. Selective 
arterial dilator
Most hypertensive emergen-
cies; caution with severe aortic 
stenosis, acute heart failure.
Allergy to egg or egg 
products, soy or any 
of  its components.
1 - 2 mg/h, 
doubling every 
90 s up to an 
infusion rate 
of  16 mg/h.
2-4 min / 
5-15 min
Atrial fibrillation 13.2-
33.6%, Nausea 5-21%, 
Headache 6%, Vomiting 
3.2%, Chest discomfort 
3.2%.
N i c a r d i -
pine
hydrochlo-
ride
Selective L-type Ca2+ 
channel antagonist. 2nd 
–generation DHP CCB-
coronary
and cerebral
arterial
vasodilation
Acute ischemic stroke or ICH, 
acute MI, acute pulmonary 
edema, aortic dissection, ec-
lampsia, hypertensive encepha-
lopathy, sympathetic crisis, may 
be used safely in pregnancy
Contraindicated in 
advanced or pre-ex-
isting aortic stenosis. 
Caution in renal and 
hepatic impaired pa-
tients.
5-15 mg/hr 5-15 min / 
4-6 hrs
Nausea, vomiting, 
headache, tachycardia, 
flushing,Phlebitis of  
veins.
Feno ldo-
pam
Mesylate
D1 (Dopamine) agonist Acute ischemic stroke, acute 
pulmonary edema or hyperten-
sive encephalopathy if  patient 
has acute or chronic renal fail-
ure, microangiopathic anemia, 
and sympathetic crisis.
Glaucoma patients 0.1 μg/kg/min 
- 1.6 μg/kg/
min.
5–10 min 
(max ima l 
- 15–30 
min) / 30-
60 min
Atrial fibrillation, dizzi-
ness, flushing, headaches, 
hypokalemia, hypoten-
sion, nausea, reflex tachy-
cardia, Worsening angina.
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Nitroglyc-
erin
Increases intracellular 
production of  cGMP.
Direct venous vasodilator Constrictive pericar-
ditis, pericardial tam-
ponade, restrictive 
cardiomyopathy, and 
the concurrent use 
of  phosphodiesterase 
inhibitors  (sildenafil, 
vardenafil) 
5 - 100 μg/min 1–5 min / 
5–20 min
Dizziness, drug toler-
ance, headaches, hy-
potension, hypoxemia, 
reflex tachycardia, wors-
ening ischemia.
S o d i u m 
Nitroprus-
side
Cyclic guanosine
monophosphate (cGMP) 
generation.
Non-selective direct dilation of  
arteries and veins
Caution in increased
intracranial pressure 
or renal impairment,
c o n t r a i n d i c a t e d 
in acute coronary 
s y n d r o m e ( AC S ) , 
acute MI, ischemic or 
hemorrhagic stroke, 
and severe coronary 
artery disease (CAD)
0.25 - 10 μg/
kg/min
1–2 min / 
1–4 min
C erebral edema, coro-
nary steal in patients 
suffering from CAD, 
diaphoresis, drug toler-
ance, flushing, headaches, 
hypotension, increased 
intracranial pressure, 
muscle twitching, nausea, 
precipitous falls in BP 
leading to overshoot and 
tissue perfusion, reflex 
tachycardia, vomiting, 
cyanide toxicity.
Hydrala-
zine
Opens K+ channels. Direct vasodilator, hyperten-
sive Emergencies.
Not suggested for 
any other hyperten-
sive emergencies
10 - 20 mg i.v. 
bolus
10–30 min 
/ 1–6 hrs
Fluid retention, flushing, 
headaches, nausea, sig-
nificant reflex tachycar-
dia, and the precipitation 
of  MI.
Esmolol β1- blocker Aortic dissection, Acute pul-
monary edema, Hypertensive 
encephalopathy.
Caution with renal
impairment or re-
stricted lung disease,
contraindications in-
clude severe brady-
cardia, bronchial 
asthma, cardiac con-
duction disorders 
including cardiogenic
shock and heart 
failure, heart block 
greater than first de-
gree, pregnancy,
and uncompensated
cardiac failure
Load 
250–1000 μg/
kg over 1–3 
min, can infuse 
25–100 μg/
kg/min, titrate 
every 5– 20 
min with a 
repeat bolus 
and increase 
drip by 25–50 
μg/kg/min up 
to a max dose 
of  300 μg/kg/
min
1–5 min 
(maximal 
effect after 
5 min) / 
10 - 30 
min
Acute pulmonary edema, 
bradycardia, bron-
chospasm, diaphoresis, 
dizziness, first degree 
heart block, flushing, 
hypotension, nausea, 
seizures, somnolence, 
thrombophlebitis, abrupt 
withdrawal may cause 
chest pain.
Labetalol Mixed alpha-1 and beta-1 
& −2 adrenergic receptor 
blocker
Acute ischemic stroke or in-
tracerebral hemorrhage (ICH),
acute myocardial infarction 
(MI), acute pulmonary edema,
aortic dissection, eclampsia, 
hyper adrenergic conditions 
such as cocaine intoxication,
hypertensive  emergency with 
acute or chronic renal failure, 
and hypertensive encephalopa-
thy, safely used in pregnancy
Caution in diabetes 
or hepatic impair-
ment, contrain-
dications include 
bronchial asthma, 
cardiogenic shock, 
chronic obstructive 
pulmonary disease, 
heart block greater 
than first degree, 
pheochromocytoma, 
reactive airway dis-
ease, severe bradycar-
dia, and uncompen-
sated cardiac failure
20 mg IV over 
2 min with  
additional 
repeated IV 
boluses every 
10 min with 
escalating 
doses of  40 
mg, 80 mg to a 
maximum, cu-
mulative dose 
of  300 mg, a 
short-term IV 
infusion of  
0.5–2.0 mg/
min may also 
be used
2–5 min / 
2–6 hrs
Bradycardia, bronchos-
pasm, dizziness, nausea, 
paresthesia, profound 
hypotension, profound 
orthostasis, scalp tin-
gling, sinoatrial/atrioven-
tricular nodal
dysfunction such as 
heart block, vomiting, 
abrupt withdrawal may 
cause acute tachycardia, 
ischemia, and rebound 
hypertension
Phentola-
mine
α-blocker Catecholamine toxicity and 
sympathetic crises such as am-
phetamine overdose, cocaine 
toxicity, clonidine withdrawal, 
and pheochromocytoma
coronary and 
cerebral
arteriosclerosis and 
renal
impairment.
5 - 15 mg i.v. 
bolus
1 - 2 min 
/ 10 - 30 
min
Flushing, dizziness, head-
ache, miosis, nasal con-
gestion, nausea, reflex 
tachycardia, vomiting, 
angina or MI in CAD 
patients
Enal-
aprilat
Arterial vasodilator, 
intravenous form of the 
angiotensin-converting 
enzyme (ACE) inhibitor 
enalapril.
Congestive heart failure, Acute 
MI
Caution in hyper-
trophic cardio-
myopathy, ischemic 
heart disease, 
preexisting renal 
insufficiency, severe 
aortic stenosis, and 
unstented renal 
artery stenosis
1.25 - 5 mg 
every 6 hrs i.v.
15 - 30 
min / 6 - 
12 hrs
BP response vari-
able. Cough, dizziness, 
headaches, hypotension 
in high renin states, 
hyperkalemia, oliguria.
International Journal of Anesthesiology & Research, 2013 © 22
Soghomonyan S et al (2013) Innovative Approaches To The Management Of Acute Arterial Hypertension - Clevidipine Butyrate. Int J Anesth Res. 1(4), 18-24 
are commonly considered as a first-line treatment of  hyperten-
sive emergencies because of  their strong vasodilatory effects and 
fewer side effects on cardiac conduction and contractility when 
compared to classes such as beta blockers [31,59,60].
Clevidipine for The Management of  Acute Hy-
pertension
Clevidipine is a third-generation, intravenous, dihydropyridine 
(DHP) calcium-channel blocker (CCB). Clevidipine was ap-
proved by the Federal Food and Drug Administration (FDA) 
of  the USA in 2008 for BP reduction when oral therapy is not 
feasible or desirable [32,33]. Clevidipine is the only intravenous 
antihypertensive approved by the FDA in the last decade. The 
drug is an ultrashort-acting vasoselective calcium antagonist for 
short-term intravenous BP control that acts on L-type calcium 
channels [34]. These channels regulate the influx of  calcium ions 
into the arterial smooth muscle cells during depolarization, and 
target excitable tissues, such as cardiac and smooth muscle, blood 
cells and neurons [32,34]. Clevidipine has high vascular selectivity, 
reducing the blood pressure by selectively dilating arterioles and 
reducing peripheral resistance, thus increasing stroke volume and 
cardiac output. It is composed of  the two enantiomers S- and R-
clevidipine. Both components of  this racemic mixture are equally 
potent and produce a similar antihypertensive effect [35,36]. Cle-
vidipine is formulated as a sterile, milky-white, ready-to-use lipid 
intravenous emulsion that is almost insoluble in water and has a 
pH of  6.0 – 8.0 [35,36]. Clevidipine is formulated in an oil-in-
water or 20% lipid emulsion of  soybean oil (200 mg/ml), contains 
approximately 0.2 g of  fat per milliliter (2.0 kcal/ml), glycerin 
(22.5 mg/ml), purified egg yolk phospholipids (12 mg/ml), and 
sodium hydroxide to adjust pH.35 Strict asepsis must be main-
tained during administration of  clevidipine infusion, because it 
contains phospholipids and can support microbial growth. If  any 
contamination is suspected, the medication must be discarded. 
Once the stopper is punctured, the drug must be used within 12 
hours. Clevidipine is administered as an intravenous infusion and 
is rapidly metabolized by plasma and extravascular esterases to an 
inactive carboxylic acid metabolite and formaldehyde molecules. 
It reaches a steady-state arterial blood concentration (Vdss 0.17 l/
kg) quickly during infusion, and the concentration declines rap-
idly post infusion, regardless of  the infusion length, resulting in a 
rapid onset as well as rapid recovery of  effect [37]. 99.7% of  clevi-
dipine is protein bound in plasma at body temperature, though no 
concentration dependent protein binding of  clevidipine has been 
observed. Clevidipine is considered a high-clearance drug with 
a mean blood clearance (CLb), independent of  body weight, of  
0.142 1/min/kg, resulting in extremely short initial (1.6 min) and 
terminal (15.5 min) half-lives. The relatively short termination of  
therapeutic effect is primarily related to the elimination rate of  the 
compound than its redistribution. The contribution of  the me-
tabolism in blood (as opposed to tissues) to the total elimination 
of  clevidipine is considered to be less than 10%. This emphasizes 
the high esterase activity in the extravascular tissues. The elimina-
tion of  clevidipine is not affected by hepatic or renal dysfunction. 
Clevidipine is excreted primarily in the urine (63 – 74%) and feces 
(7 – 22%) within the first 72 h after administration [38].
Clevidipine is administered as an intravenous infusion via a periph-
eral or central venous catheter. The medication is contraindicated 
in patients with allergies to soy products, eggs, and egg products, 
or defective lipid metabolism.  The onset of  action of  intravenous 
clevidipine is within 2-4 minutes, when it produces a 4-5% de-
crease in SBP. After initiation of  clevidipine intravenous infusion, 
the clevidipine plasma concentration decreases in a biphasic pat-
tern. During the first phase, 85-90% of  clevidipine is eliminated 
with an elimination half-life of  1 minute and a terminal half-life 
of  15 minutes [32]. Clevidpine is a specific arteriolar dilator, caus-
ing a decrease in arterial resistance and leading to a decrease in 
mean BP [37]. Because of  selective action on arteriols, clevidpine 
has minimal or no effects on heart rate, myocardial contractility, 
conduction, cardiac output and stroke volume [18,28].
Owing to the drug’s pharmacological profile, which includes rapid 
onset of  action, small volume of  distribution, and high clearance, 
clevidipine can be considered an ideal agent in patients with AHE. 
Clinical studies with clevidipine have consistently demonstrated 
its safety and efficacy in patients with acute hypertensive episodes 
requiring treatment with parental antihypertensive medications.
Pharmacodynamic and pharmacokinetic properties of  clevidipine 
had been evaluated in healthy volunteers in clinical trials. Intrave-
nous clevidipine was shown to have a short duration of  action, 
short half-life, high clearance rate and fast elimination. Clevidi-
pine was rapidly titratable, safe and well tolerated [37,38,39]. 
In Phase II trials, racemic formulation of  clevidipine was pre-
ferred over the individual enantiomer formulations to achieve 
clinical efficacy in patients with essential hypertension. The tri-
als also demonstrated the dose dependent relationship between 
clevidipine and BP (SBP & DBP) reduction; which allowed for 
predictable dose responses and a more efficient control of  hyper-
tension to desired BP ranges [40,41].
During the Phase III trials with clevidipine, the medication was 
evaluated in patients undergoing elective cardiac surgery. In these 
trials, clevidipine efficiently reduced the MAP, and systemic vascu-
lar resistance (27% at maximal infusion rate) in a dose-dependent 
fashion. Clevidipine infusion was associated with hemodynamic 
stability (heart rate, central venous pressure and cardiac index). 
No changes in cardiac lactate metabolism were revealed in doses 
used to treat the systemic hypertension [42,43,44]. 
Levy et al., and Singla et al., studied clevidipine in two randomized 
double blind, placebo controlled trials in preoperative and post-
operative cardiac surgery patients respectively (ESCAPE1 and 
ESCAPE2). In both studies the target SBP was achieved within 
4-7 minutes, the success rate of  controlling the SBP was 92.5% 
and 91.8% respectively [45,46]. Aronson S et al., in their large 
randomized controlled trial (ECLIPSE trial) evaluated the efficacy 
of  clevidipine compared with sodium nitroprusside, nitroglycerin 
(perioperatively), or nicardipine (postoperatively) in elective car-
diac surgery patients. In this study, the clevidipine group achieved 
superior BP control compared with other drugs. Clevidipine 
therapy was also associated with a significantly lower 30-day post-
operative mortality than sodium nitroprusside [47]. In the VE-
LOCITY trial (Pollack et al.), clevidipine’s safety and efficacy were 
evaluated in patients with severe hypertension in the emergency 
room or intensive care unit. In these patients, the clevidipine infu-
sion continued for up to 96 hours. In 88.9% of  patients the tar-
get SBP achieved within 30minutes (median time - 10.9 minutes). 
Only 1.6% of  patients experienced decrease in SBP below the 
target range. At least one adverse effect was observed in 39.7% of  
patients, with 8.7% of  them considered serious. Adverse effects 
(in descending order) included headache, nausea, chest discom-
fort, and vomiting [48].
The ACCELERATE trial (Graffagnio et al.), was designed as a 
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multicenter, single arm study. It evaluated the use of  clevidipine 
for the management of  severe hypertension in patients with in-
tracerebral hemorrhage. Clevidipine was effective in reducing the 
SBP to a target range of  less than 160 mm Hg in 97% patients 
within 3-10 minutes [49]. Bekker et al., evaluated the use of  cle-
vidipine in controlling the perioperative hypertension in elective 
neurosurgical patients. They found that SBP values were reduced 
to target levels within 15minutes in 78.6% of  times after initiation 
of  infusion. The researchers concluded that clevidipine was an 
effective and safe drug that could be effectively used to control 
the perioperative hypertension in patients undergoing intracranial 
procedures [50]. Varelas PN et al., evaluated the role of  clevidi-
pine in their open-label pilot study in patients undergoing clip-
ping or coiling of  aneurysm for acute hypertension in patients 
with subarachnoid hemorrhage. They concluded that clevidipine 
controlled the SBP in < 22 minutes and kept the values within the 
elective range 70% of  the time without major complications [51]. 
Clevidipine can also be used for intraoperative BP control in pa-
tients with suspected diagnosis of  pheochromocytoma or during 
elective pheochomocytoma resection. In both case reports the 
BP was well controlled with clevidipine infusion [52,53]. Further 
studies with larger numbers of  patients will be required to assess 
clevidipine efficacy in this patient group relative to the tradition-
ally used medications.
It is not clear whether, clevidipine is safe during pregnancy, labor 
and breast feeding. It is known that the drug is being excreted in 
milk. In animals, clevidipine increases fetal and maternal mortality 
and the gestational duration. Until better evidence becomes avail-
able, clevidipine during pregnancy may be recommended for use 
only in those cases when treatment benefits will clearly outweigh 
the potential risks [32].
The safety of  clevidipine in pediatric population (<18 years) is 
unknown. The drug’s use in pediatric patients has been reported 
in case reports and retrospective reviews, however, no prospec-
tive studies have been conducted. Clevidipine-based therapy of  
hypertension in pediatric population was first reported in a 16-
year old patient to control AH during the urgent placement of  a 
peritoneal dialysis catheter [54]. Taking into account the pharma-
cokinetic and pharmacodynamic properties of  clevidipine in adult 
population, it has been used in pediatric spine and cardiac surgery 
to provide controlled hypotension and control perioperative AH 
respectively. The lowest age of  the pediatric patient treated with 
clevidipine in these retrospective analyses was 11 months. This 
drug has proved its efficacy in adequately controlling BP with 
minimal side effects [55,56,57]. Clevidipine’s pharmacokinetic 
profile in children is similar to that for adults showing rapid me-
tabolism by non-specific blood and tissue esterase’s with a short 
half-life (<1min) [58]. Nevertheless, properly-designed prospec-
tive clinical trials are needed to evaluate the efficacy, safety and 
side effects of  clevidipine in the pediatric population.
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